Antidepressants and sexual health – How to improve patients’ quality of life?

Introduction: Depression is one of the most common psychiatric disorders, with its prevalence continuously increasing. Consequently, more individuals are using antidepressants and experiencing various adverse effects. One of the important, yet often overlooked, side effect of depression pharmacotherapy is sexual dysfunction. This article aims to review sexual dysfunction associated with antidepressant therapy, explore available management strategies, and highlight emerging therapeutic options. Materials and methods: A literature review was performed using the PubMed and Scopus databases, covering publications from 2020 to 2024 focused on antidepressant-induced sexual dysfunction. Open-access publications in English-language were included, comprising original research articles, systematic reviews, meta-analyses, and narrative reviews. Results: The most frequently reported antidepressant-related sexual dysfunctions include decreased libido, delayed ejaculation, anorgasmia, and erectile dysfunction. These effects are most often observed in patients treated with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). A lower, though still relevant, risk is associated with tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). Medications such as vortioxetine, agomelatine, vilazodone, and bupropion offer promising therapeutic alternatives with a reduced risk of sexual side effects. Moreover, growing evidence supports the effectiveness of adjunctive and non-pharmacological interventions. Conclusions: Sexual dysfunctions significantly impair patients’ quality of life and often lead to treatment discontinuation and recurrence of depressive symptoms. Despite their prevalence, many patients do not report these symptoms due to embarrassment, which underscores the need for a conscious, empathetic approach from doctors. Active monitoring and implementing effective strategies to minimise these side effects without compromising antidepressant efficacy are essential.

Authors

Institutions

Publication Details

Journal
Current Problems of Psychiatry
Published
2025-10-23
DOI
https://doi.org/10.12923/2353-8627/2025-0010
Primary Topic
Sexual function and dysfunction studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Antidepressants and sexual health – How to improve patients’ quality of life?

W. Woźniak, Ewelina Soroka, Katarzyna Wiktoria Witczak, Zuzanna Winiarska et al.
Current Problems of Psychiatry
Sexual function and dysfunction studies
article

Antidepressants and sexual health – How to improve patients’ quality of life?

W. Woźniak, Ewelina Soroka, Katarzyna Wiktoria Witczak, Zuzanna Winiarska, Marcin Wieleba
article en

Abstract

Introduction: Depression is one of the most common psychiatric disorders, with its prevalence continuously increasing. Consequently, more individuals are using antidepressants and experiencing various adverse effects. One of the important, yet often overlooked, side effect of depression pharmacotherapy is sexual dysfunction. This article aims to review sexual dysfunction associated with antidepressant therapy, explore available management strategies, and highlight emerging therapeutic options. Materials and methods: A literature review was performed using the PubMed and Scopus databases, covering publications from 2020 to 2024 focused on antidepressant-induced sexual dysfunction. Open-access publications in English-language were included, comprising original research articles, systematic reviews, meta-analyses, and narrative reviews. Results: The most frequently reported antidepressant-related sexual dysfunctions include decreased libido, delayed ejaculation, anorgasmia, and erectile dysfunction. These effects are most often observed in patients treated with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). A lower, though still relevant, risk is associated with tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). Medications such as vortioxetine, agomelatine, vilazodone, and bupropion offer promising therapeutic alternatives with a reduced risk of sexual side effects. Moreover, growing evidence supports the effectiveness of adjunctive and non-pharmacological interventions. Conclusions: Sexual dysfunctions significantly impair patients’ quality of life and often lead to treatment discontinuation and recurrence of depressive symptoms. Despite their prevalence, many patients do not report these symptoms due to embarrassment, which underscores the need for a conscious, empathetic approach from doctors. Active monitoring and implementing effective strategies to minimise these side effects without compromising antidepressant efficacy are essential.

Current Problems of PsychiatryVol. 26
Medical University of Lublin (PL)
Openalex Percentile: Top 64%
Sexual function and dysfunction studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.